Microbix Biosystems

Watline Avenue | Microbix Biosystems Inc. Microbix Biosystems Inc. develops biological products and technologies. The Company was founded in 1988 as a producer of Infectious Disease Antigens, primarily for the diagnostics market. The Company invests in the virology business to build capacity and develop new products to address emerging market opportunities, while enhancing manufacturing and laboratory capabilities and technologies. Building on expertise in virology and protein biochemistry, the Company developed a pipeline of selected biological technologies including VIRUSMAX (Influenza Virus Yield Enhancement Technology), LumiSort™ (Semen Sexing Technology) and the thrombolytic drug, Kinlytic® (Urokinase). Funded by income from the antigen business, the pipeline products take aim at large market opportunities. With Microbix’ core competencies in the Infectious Disease Antigen business, including cell culture, molecular biology, and a GMP quality system, the pipeline products build on Microbix’ strength.

Microbix Biosystems headquartered in North America, operates in the Biotechnology, Manufacturing, Health Diagnostics sector. The company focuses on Biotechnology and has secured $488.9M in funding across 72 round(s). With a team of 51-100 employees, Microbix Biosystems is actively contributing to advancements in Biotechnology. Their latest funding round, Post-IPO Equity - Microbix Biosystems, raised $248.0K. Discover more about their projects, partnerships, and impact on our platform.